tradingkey.logo

BRIEF-Basilea Pharmaceutica Expects Revenue To Rise 5.5% To CHF 220 Mln in 2025

ReutersFeb 18, 2025 6:19 AM

- BASILEA PHARMACEUTICA AG BSLN.S:

  • OUTLOOK 2025: TOTAL REVENUE IS EXPECTED TO INCREASE BY 5.5% TO CHF 220 MILLION DRIVEN BY AN INCREASE IN BARDA AND CARB-X REIMBURSEMENTS

  • OUTLOOK 2025: MILESTONE AND UPFRONT PAYMENTS IN 2025 ARE EXPECTED TO BE IN AVERAGE RANGE OF LAST FEW YEARS OF AROUND CHF 35 MILLION

  • OUTLOOK 2025: EXPECT TO MAINTAIN HIGH OPERATING PROFIT LEVEL OF 2024

  • OUTLOOK 2025: 12% INCOME TAX RATE WILL BE REFLECTED IN 2025 NET PROFIT

  • AFTER SERVING ON BOARD OF DIRECTORS FOR 14 YEARS, DOMENICO SCALA HAS DECIDED NOT TO STAND FOR RE-ELECTION

  • BOARD HAS NOMINATED STEPHAN SCHINDLER FOR ELECTION AS A NEW BOARD MEMBER AND CHAIRMAN

Source text: ID:nGNXbB945K

Further company coverage: BSLN.S

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI